Drugs / Paclitaxel albumin-bound
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07259590 | Oct 2025 → Jul 2027 expected | colorectal cancer, pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07492342 Background | Jan 2026 → Mar 2027 expected | acute myeloid leukemia, KRAS gene mutation, non-small cell lung carcinoma | Jianxing He | Recruiting | No outcome recorded |
| Phase 2 | NCT04760431 Background | Oct 2021 → Sep 2024 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel (Albumin bound) | “Paclitaxel (albumin-bound) at 125 mg/m² and gemcitabine at 1000 mg/m² will be administered via intravenous infusion” NCT07259590 ↗2“Paclitaxel albumin-bound injection: 100 mg per vial; 260 mg/m² intravenously every 3 weeks” NCT07492342 ↗ “Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks” NCT04760431 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT04760431 ↗ |